Delving into the Latest Updates on Ecabet Sodium Hydrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ecabet, Ecabet Sodium, Ecabet Sodium Granules

+ [7]

Target-

Action

inhibitors

Mechanism

Urease inhibitors

Therapeutic Areas

Digestive System Disorders

Active Indication

Acute gastritisChronic gastritisStomach Ulcer

Inactive Indication

Colitis, UlcerativeDry Eye Syndromes

Originator Organization

Mitsubishi Tanabe Pharma Corp.

Active Organization

Mitsubishi Tanabe Pharma Corp.BCWORLD PHARM. Co., Ltd.

Inactive Organization

Senju Pharmaceutical Co., Ltd.

ISTA Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

Japan (01 Oct 1993),

Stomach Ulcer

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC20H28NaO5S

InChIKeyJNTMHWBQZJIWMT-YGJXXQMASA-N

CAS Registry86408-72-2

View All Structures (2)

Herein, an N-coordinated Fe site dispersed in porous carbon frameworks (Fe-NC) fabricated from zeolitic imidazolate frameworks encapsulated with iron acetylacetonate (Fe(acac)₃ @ZIFs) was employed to activate peroxymonosulfate (PMS) for the attenuation of sulfisoxazole (SIZ) and treating real hospital wastewater. The constructed Fe-NC/PMS system exhibited good catalytic stability for SIZ degradation, maintaining excellent degradation performance over multiple cycles with virtually no leaching. The quenching experiments, electron paramagnetic resonance (EPR) capture analyses, and semi-quantitative measurements showed that singlet oxygen (¹O₂) and high-valent metal-oxo species were mainly responsible for SIZ degradation by Fe-NC/PMS. Significantly, ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS/MS) was used to trace 134 pharmaceutical contaminants in real hospital wastewater. Effective degradation was achieved for 87 % of the pharmaceutical contaminants by the Fe-NC/PMS process. Seventy-four pharmaceutical contaminants were eliminated. Taken together, this work successfully established the Fe-NC/PMS technology using the developed iron-based materials and explored its application to real hospital wastewater treatment, providing an eco-friendly and effective strategy for treating wastewater.

01 Jan 2023·Plant Biotechnology Journal

Structural and mechanistic insights into the precise product synthesis by a bifunctional miltiradiene synthase

Article

Author: Chen, Kang ; Cui, Guanghong ; Jiang, Tao ; Tong, Yuru ; Huang, Luqi ; Gao, Wei ; Ma, Xiaoli ; Su, Ping ; Xu, Haifeng ; Hu, Tianyuan

SummarySelaginella moellendorffii miltiradiene synthase (SmMDS) is a unique bifunctional diterpene synthase (diTPS) that catalyses the successive cyclization of (E,E,E)‐geranylgeranyl diphosphate (GGPP) via (+)‐copalyl diphosphate (CPP) to miltiradiene, which is a crucial precursor of important medicinal compounds, such as triptolide, ecabet sodium and carnosol. Miltiradiene synthetic processes have been studied in monofunctional diTPSs, while the precise mechanism by which active site amino acids determine product simplicity and the experimental evidence for reaction intermediates remain elusive. In addition, how bifunctional diTPSs work compared to monofunctional enzymes is attractive for detailed research. Here, by mutagenesis studies of SmMDS, we confirmed that pimar‐15‐en‐8‐yl+ is an intermediate in miltiradiene synthesis. Moreover, we determined the apo‐state and the GGPP‐bound state crystal structures of SmMDS. By structure analysis and mutagenesis experiments, possible contributions of key residues both in class I and II active sites were suggested. Based on the structural and functional analyses, we confirmed the copal‐15‐yl+ intermediate and unveiled more details of the catalysis process in the SmMDS class I active site. Moreover, the structural and experimental results suggest an internal channel for (+)‐CPP produced in the class II active site moving towards the class I active site. Our research is a good example for intermediate identification of diTPSs and provides new insights into the product specificity determinants and intermediate transport, which should greatly facilitate the precise controlled synthesis of various diterpenes.

01 Dec 2022·Russian Journal of General Chemistry

Biotesting in an Environmental Monitoring System: Safety Assessment of Rosin Derivatives

Author: Nikitina, A. M. ; Popova, L. M. ; Tsyrulnikova, A. S. ; Ivanchenko, O. B. ; Vershilov, S. V.

According to the PASS prediction, resin acids and rosin derivatives can exhibit protective activity with respect to mucous membranes (Pa 71-98%).Therefore, these substances can form the basis for drug development, which includes biotesting as a necessary step in biosafety assessment of drug candidates.Study of antibacterial activity by the disk diffusion method showed that the most toxic effect on E. coli and B. subtilis cells is characteristic of gum rosin, maleopimaric acid, and abietinol.Gum rosin exhibits fungicidal activity against C. tropicalis yeast. 12-Sulfodehydroabietic acid and its potassium salt affect the intensity of seed germination of Raphanus sativusL., and their toxicity is directly related to concentrationComplete inhibition of seed germination is observed at a concentration of 25 mg/mL.

100 Deals associated with Ecabet Sodium Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01991	-	A02B	DB05265

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute gastritis	Japan	Mitsubishi Tanabe Pharma Corp.	22 Nov 1995
Chronic gastritis	Japan	Mitsubishi Tanabe Pharma Corp.	22 Nov 1995
Stomach Ulcer	Japan	Mitsubishi Tanabe Pharma Corp.	01 Oct 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	NDA/BLA	Japan	Mitsubishi Tanabe Pharma Corp.	-
Dry Eye Syndromes	NDA/BLA	United States	ISTA Pharmaceuticals, Inc.	-
Dry Eye Syndromes	NDA/BLA	Japan	Senju Pharmaceutical Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00667004 (CTgov)	Phase 2	Dry Eye Syndromes	183	Ecabet (Ecabet Ophthalmic Solution)	totrjdweoi(bmighxwdrf) = vfeagmnisp xuovmwsuxf (annakfosnw, znsxmlwcfj - yrhvtqozbb) View more	-	03 Sep 2020
				placebo (Vehicle)	totrjdweoi(bmighxwdrf) = fvfvsnkiuv xuovmwsuxf (annakfosnw, jwlfzcifuv - yzdsdcbeyj) View more